• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human IGFBP-2 protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0823

Validation Data Gallery

  • Purity of Recombinant Human IGFBP-2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human IGFBP-2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human IGFBP-2 protein Ala36-Gln325 (Accession# P18065) with a His tag at the C-terminus.
GeneID 3485
Accession P18065
PredictedSize 32.5 kDa
SDS-PAGE 29-34 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IGFBP2, also known as BP2 and IBP2, is a member of the IGFBP family. It is predominantly expressed in fetal tissues that are highly proliferative, such as the early post-implantation epiblast, the ventricular zone of the rostral neuroepithelium, and has been found to be highly expressed in many cancers. It is a promising protein in non-communicable diseases such as obesity, insulin resistance, metabolic syndrome or type 2 diabetes. IGFBP2 mediates IGF-independent tumorigenesis by participating in intracellular and nuclear regulatory networks and may serve as an excellent prognostic biomarker in various cancers.

References:

1. Li T. et al. (2020) Oncogene. 39(11):2243-2257. 
2. Boughanem H. et al. (2021) Int J Mol Sci. 22(3):1133. 
3. Zhang B. et al. (2022) Cancer Med. 11(16):3035-3047.